Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Herombopag vs placebo for chemotherapy-induced thrombocytopenia (Phase III, randomized double-blind multicenter trial)
CTR20230800Phase 3Active
- Sponsor
- Hengrui Therapeutics
- Start
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chemotherapy-induced thrombocytopenia (CIT) comparing Herombopag Olamine Tablets with Placebo (Herombopag-matched simulation tablets) (2 arms). Primary endpoint: Proportion of patients achieving treatment effectiveness during double-blind period. Started Apr 2023; status: active.
02
Drugs
hetrombopag
03
Conditions
chemotherapy-induced thrombocytopenia (CIT)
Beyond the preview
Go deeper on CTR20230800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230800.